StreetInsider.com News Articles

Form 4 Beam Therapeutics Inc. For: Oct 15 Filed by: Evans John M.

Fri, 16 Oct 2026 20:10:00 -0400

si-local-file:///var/storage/secattach/20261016/27199026.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Fri, 16 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261016/27198062.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Thu, 15 Oct 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20261015/27193692.html

Beam Therapeutics reports early trial data for GSDIa gene therapy

Tue, 13 Oct 2026 07:00:16 -0400

Beam Therapeutics Inc. (Nasdaq: BEAM) announced it will present initial data from its ongoing Phase 1/2 clinical trial of BEAM-301, a base editing therapy for glycogen storage disease type Ia (GSDIa), at the 33rd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) in Hamburg, Germany, on October 28, 2026.

As of a June 26, 2026, data cutoff, six patients received a single intravenous infusion of BEAM-301 — three at 20 mg and three at 40 mg. Median follow-up was 313 days in the 20 mg cohort and 53 days in the 40 mg cohort. One patient in

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

Tue, 13 Oct 2026 07:00:00 -0400

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa

Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints

Safety Profile of BEAM-301 Consistent with LNP-based Therapies

Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET

CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present initial data

Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress

Tue, 13 Oct 2026 07:00:00 -0400

BEAM-301 Achieves Clinical Proof of Concept for Genetic Correction of R83C Mutation in GSDIa

Initial Phase 1/2 Data Show Restoration of Endogenous Glucose Production Following a Single Treatment, with Dose-Dependent Improvements in Key GSDIa Endpoints

Safety Profile of BEAM-301 Consistent with LNP-based Therapies

Beam to Host Investor Webcast on Tuesday, October 27, 2026, at 8:00 a.m. ET

Form 4 Beam Therapeutics Inc. For: Oct 01 Filed by: Cavanagh Bethany J

Fri, 02 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261002/27142100.html

Form 4 Beam Therapeutics Inc. For: Sep 24 Filed by: Ciaramella Giuseppe

Fri, 25 Sep 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260925/27107363.html

Beam Therapeutics shares updated BEAM-302 trial data at ERS 2026

Tue, 08 Sep 2026 06:00:21 -0400

Beam Therapeutics (Nasdaq: BEAM) presented updated clinical data from its Phase 1/2 trial of BEAM-302, a base editing therapy for alpha-1 antitrypsin deficiency (AATD), at the European Respiratory Society Congress in Barcelona, Spain, on Sept. 8, 2026.

As of Aug. 17, 2026, 38 patients have received BEAM-302 across two trial cohorts. Data presented at the conference covered 29 patients in the dose-escalation portion of the study, with follow-up of up to 18 months. The data cutoff date was June 24, 2026.

At the 60 mg dose in Part A, circulating total AAT reached a mean of 14.4 µM and median of 15.2

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Tue, 08 Sep 2026 06:00:00 -0400

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control

With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302

Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation

BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers

Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies

Dosing Underway

Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026

Tue, 08 Sep 2026 06:00:00 -0400

BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control

With Up to 18 Months Follow-Up, Data Show Long-Term Durability of In Vivo Correction of Disease-causing Mutation with Single Dose of BEAM-302

Treatment with BEAM-302 Increased Total and Functional AAT and Decreased Neutrophil Elastase Activity in Circulation

BEAM-302 Led to Reduction in Circulating Mutant Z-AAT and Corresponding Decrease in Toxic Circulating Z-polymers

Safety Profile of BEAM-302 Remains Consistent with LNP-based Therapies

Dosing Underway

Beam Therapeutics names Eric Foster as chief commercial officer

Tue, 01 Sep 2026 07:00:29 -0400

Beam Therapeutics Inc. (Nasdaq: BEAM) has appointed Eric Foster as chief commercial officer, the Cambridge, Mass.-based biotechnology company announced.

Foster brings more than 25 years of commercial experience in biotechnology and specialty pharmaceuticals. He most recently served as chief commercial officer at Ardelyx. Before that, he was senior vice president and U.S. general manager at Amgen, a role he assumed following Amgen's acquisition of Horizon Therapeutics in October 2023.

At Horizon, Foster served as senior vice president and general manager of the gout and ophthalmology business units, overseeing franchises that generated $2.75 billion in net sales revenue. From 2010 to 2021, he

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Tue, 01 Sep 2026 07:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

“Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are

Beam Therapeutics Appoints Eric Foster as Chief Commercial Officer

Tue, 01 Sep 2026 07:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Eric Foster as chief commercial officer. Mr. Foster will lead Beam’s commercial organization and strategy as the company advances multiple product candidates across its hematology and genetic disease franchises toward potential launches.

“Eric is an exceptional biopharmaceutical leader with a proven track record of building high-performing commercial organizations in specialty and rare disease markets,” said John Evans, chief executive officer of Beam Therapeutics. “His decades of commercial leadership are

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

Beam Therapeutics to Participate in Upcoming September 2026 Investor Conferences

Mon, 31 Aug 2026 07:00:00 -0400

CAMBRIDGE, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will participate in fireside chats at the following upcoming investor conferences:

Wells Fargo 21^st Annual Healthcare Conference on Tuesday, September 8, 2026 at 1:30 p.m. ET in Boston
Citi’s Biopharma Back to School Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET in New York
Cantor Fitzgerald Global Healthcare Conference 2026 on Thursday, September 10, 2026 at 8:00 a.m. ET in New York

The live

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Tue, 25 Aug 2026 06:58:36 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst commented: "On August 20, we hosted an H.C. Wainwright At Home virtual fireside chat with Beam Therapeutics President and CEO John Evans, focused on BEAM-302 in alpha-1 antitrypsin deficiency (AATD), risto-cel in sickle cell disease (SCD), and the FDA-cleared BEAM-304 umbrella investigational new drug application (IND) in phenylketonuria (PKU). In AATD, the goal includes moving ZZ patients from mid-single-digit total alpha-1 antitrypsin (AAT) composed almost entirely of mutant Z protein into double-digit AAT with an inverted M:Z ratio and preserved

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC

Fri, 14 Aug 2026 14:56:00 -0400
si-local-file:///var/storage/secattach/20260814/26929246.html

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: ARK Investment Management LLC

Fri, 14 Aug 2026 14:56:00 -0400
si-local-file:///var/storage/secattach/20260814/26929246.html

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:14:00 -0400
si-local-file:///var/storage/secattach/20260813/26922695.html

Form SCHEDULE 13G/A Beam Therapeutics Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.

Thu, 13 Aug 2026 17:14:00 -0400
si-local-file:///var/storage/secattach/20260813/26922695.html

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Mon, 10 Aug 2026 06:43:04 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst commented: "On August 4, Beam reported 2Q26 results and disclosed that in July it dosed the first patient in the global pivotal cohort of the ongoing Phase 1/2 trial evaluating BEAM-302 in patients with AATD-associated lung disease, with or without liver disease, in a cohort designed to support a potential accelerated approval path in the U.S. (link to deck). Detailed and updated BEAM-302 clinical data were selected for a late-breaking oral presentation at the European Respiratory Society (ERS) Congress, September

Beam Therapeutics Inc (BEAM) PT Raised to $240 at JPMorgan

Wed, 05 Aug 2026 08:11:50 -0400
JPMorgan analyst Brian Cheng raised the price target on Beam Therapeutics Inc (NASDAQ: BEAM) to $240.00 (from $225.00) while maintaining a Overweight rating.